Bridging causal biology and breakthrough protein engineering.
Targeting causal biology...
Overactive Activin and GDF signaling has been established as a causal driver of Pulmonary Hypertension, Heart Failure and Obesity by genetic, translational and clinical evidence.
Multiple Activin and GDF ligands act in a redundant and compensatory fashion to drive these diseases.
Simultaneous blocking of multiple Activin and GDF ligands is required for optimal therapeutic effect due to the redundant and compensatory nature of these growth factors.
...with next-generation ligand traps.
Due to their inherent multi-specificity, ligand traps hold the unique power to effectively and precisely target Activin and GDF biology.
We leveraged a novel combinatorial protein engineering approach that integrates precision mutagenesis with diverse spatial presentations of the mutated ligand-binding domains.
This novel engineering approach unlocks previously inaccessible protein design space, enabling us to overcome the limitations of older generation traps that lacked both selectivity and potency.
This allows us to purposefully engineer the next-generation of Activin x GDF ligand traps with tailored neutralization profiles and class-leading therapeutic indices.
Development
Targeting high probability of success indications
supported by strong evidence of Activins and GDFs as causal drivers to maximize clinical success.
Biomarker-informed, efficient development plans
that aim to deliver rapid Proof-of-Principle for the potential benefit of our drug candidates in patients.
Powered by decades of experience, enhanced by structure-based AI-assisted rational design
Our team leverages deep expertise in complex biologics design, development, and manufacturing, combined with advanced computational and experimental methods.
Subscribe
To receive our press releases, please subscribe to our mailing list
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.